NHS Hospitals Admit Significant Errors in Palantir Contract Data
Alina Collins
Multiple NHS hospital trusts have confirmed that data behind the core claim — a 15% drop in delayed discharges thanks to Palantir's platform — contains widespread errors. 42% of trusts show data anomalies, and a parliamentary push, a regulatory probe and the data-quality dispute are converging on next spring's contract renewal.
How did the "15% improvement" number fall apart?
NHS England claimed hospitals using Palantir's Federated Data Platform (FDP) saw delayed discharges drop by 15%.
A Financial Times analysis found that some hospitals' delay figures plunged from hundreds or thousands to zero, then spiked back up — a pattern near-impossible in reality.
This means → the "15% improvement" conclusion rests on data that is itself unreliable. Four trusts have confirmed the underlying data is wrong.
How widespread is the data-quality problem?
The FT reviewed four years of acute discharge data and found anomalies in 42% of NHS hospital trusts.
NHS England's own website acknowledges the dataset has undergone only "minimal" quality checks.
In plain terms = this is not a handful of data-entry mistakes — nearly half of all trusts have problematic data. Drawing any conclusion about a platform's effectiveness from that base is inherently unsound.
Is Palantir responsible for the bad data?
No. The data comes from an NHS England national mandatory dataset. Palantir has no oversight of it.
In plain terms = Palantir analyses the data, but NHS itself collects it and owns its quality — the problem is at the source, not in the analytics tool.
This reflects a deeper issue: NHS rushed to show platform benefits without first ensuring the data foundation was solid.
Why was NHS under pressure to show results early?
NHS officials admit there was internal pressure to demonstrate FDP benefits prematurely.
One official said trusts were "asked to endorse improvements before the tool was fully deployed and before evaluations were complete."
This means → the reported "benefits" were not post-evaluation conclusions — they were narratives assembled under pressure, ahead of schedule.
Where do the regulatory probe and parliamentary push stand?
The UK statistics regulator has opened an investigation into core FDP claims and is "reviewing the issues raised in the article."
Cross-party members of the Health Select Committee wrote to ministers this week, urging the government to use exit clauses to terminate the Palantir contract by next spring.
NHS England CEO Sir Jim Mackey told a parliamentary committee he had questioned whether the benefits assessment was "objective and able to withstand challenge," and called an "objective" review "necessary and helpful" — but warned it would take months.
What happens next spring?
Former Health Secretary Wes Streeting ordered an internal review before leaving office. His successor will decide whether to end the contract.
NHS England's spokesperson cited an independent evaluation saying Palantir's Optica tool "saved staff time and reduced unnecessary hospital days after treatment."
This means → parliamentary pressure, a regulatory investigation and the data-quality dispute are all converging on the spring contract-renewal deadline — the decisive test of whether Palantir can hold its position in the UK healthcare market.
Content is for reference only, not financial advice.